take profit: $17
Celldex Therapeutics, Inc. Analyst Rating Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The company received an average rating of 1 from 8 analysts. 8 have rated it as a strong buy.
Many analysts have commented on the...